Law & Regulation
Algernon sells Ifenprodil, zooms in on DMT for stroke care
The upcoming study will compare the effects of DMT and a placebo in stroke patients.
The post Algernon sells Ifenprodil, zooms in on DMT for stroke care…
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) announced Monday that it will prioritize the development of its intravenous formulation of AP-188 (DMT) to see if it can help patients recover from strokes.
The decision follows the Canadian clinical-stage pharmaceutical’s Wednesday sale of its Ifenprodil research program to Seyltx, a U.S.-based private drug developer, for $2 million in cash and a 20% equity stake in Seyltx.
Algernon’s subsidiary, Algernon NeuroScience, will lead the research and development of the DMT stroke program. The subsidiary already completed a feasibility study and finalized the design for a 40-patient Phase 2a clinical trial, which will investigate the use of a sub-psychedelic dose of DMT administered intravenously to patients hospitalized after suffering an acute ischemic stroke.
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” Algernon CEO Christopher J. Moreau said in a statement. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
The Phase 2a study will primarily focus on safety while also gathering data on efficacy measures such as brain tissue preservation, motor recovery, depression, and various biomarkers associated with stroke pathophysiology.
The choice to move forward with the research was encouraged by earlier small-scale studies that showed DMT could induce brain repair effects at non-psychedelic doses during a six-hour treatment session.
“The amount given exceeded the human equivalent of the dose used in preclinical studies in rats, which demonstrated neuroprotective effects,” the company said.
The post Algernon sells Ifenprodil, zooms in on DMT for stroke care appeared first on Green Market Report.
research psychedelic dmt-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics